You are here

Article Text

Article menu
Download PDFPDF
DTB select
Molnupiravir provides little benefit in vaccinated adults with COVID-19

Abstract

Overview of: Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2023;401:281–93.

  • Health Care Quality, Access, and Evaluation
  • Drug-Related Side Effects and Adverse Reactions

https://doi.org/10.1136/dtb.2023.000020

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.